News
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback